Top

Published in:

Open Access 01-12-2010 | Review

Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways

Authors: Constance Lay-Lay Saw, Qing Wu, Ah-NgTony Kong

Published in: Chinese Medicine | Issue 1/2010

Abstract

This article reviews recent basic and clinical studies of ginseng, particularly the anti-cancer effects and the potential chemopreventive actions by activating the transcriptional factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2 or NFE2L2)-mediated anti-oxidative stress or anti-inflammatory pathways. Nrf2 is a novel target for cancer prevention as it regulates the antioxidant responsive element (ARE), a critical regulatory element in the promoter region of genes encoding cellular phase II detoxifying and anti-oxidative stress enzymes. The studies on the chemopreventive effects of ginseng or its components/products showed that Nrf2 could also be a target for ginseng's actions. A number of papers also demonstrated the anti-inflammatory effects of ginseng. Targeting Nrf2 pathway is a novel approach to the investigation of ginseng's cancer chemopreventive actions, including some oxidative stress and inflammatory conditions responsible for the initiation, promotion and progression of carcinogenesis.

Available only for authorised users

Gillis CN: Panax ginseng pharmacology: a nitric oxide link?. Biochem Pharmacol. 1997, 54 (1): 1-8. 10.1016/S0006-2952(97)00193-7.CrossRefPubMed

Yue PY, Mak NK, Cheng YK, Leung KW, Ng TB, Fan DT, Yeung HW, Wong RN: Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. Chin Med. 2007, 2: 6-10.1186/1749-8546-2-6.PubMedCentralCrossRefPubMed

Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev. 2004, 9 (3): 259-274.PubMed

Saita T, Katano M, Matsunaga H, Kouno I, Fujito H, Mori M: Screening of polyacetylenic alcohols in crude drugs using the ELISA for panaxytriol. Biol Pharm Bull. 1995, 18 (7): 933-937.CrossRefPubMed

Matsunaga H, Saita T, Nagumo F, Mori M, Katano M: A possible mechanism for the cytotoxicity of a polyacetylenic alcohol, panaxytriol: inhibition of mitochondrial respiration. Cancer Chemother Pharmacol. 1995, 35 (4): 291-296. 10.1007/BF00689447.CrossRefPubMed

Yun TK: Panax ginseng--a non-organ-specific cancer preventive?. Lancet Oncol. 2001, 2 (1): 49-55. 10.1016/S1470-2045(00)00196-0.CrossRefPubMed

Li W, Kong AN: Molecular mechanisms of Nrf2-mediated antioxidant response. Mol Carcinog. 2009, 48 (2): 91-104. 10.1002/mc.20465.PubMedCentralCrossRefPubMed

Gum SI, Jo SJ, Ahn SH, Kim SG, Kim JT, Shin HM, Cho MK: The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J Ethnopharmacol. 2007, 112 (3): 568-576. 10.1016/j.jep.2007.05.014.CrossRefPubMed

Ng F, Yun H, Lei X, Danishefsky SJ, Fahey J, Stephenson K, Flexner C, Lee L: (3R, 9R, 10R)-Panaxytriol: A molecular-based nutraceutical with possible application to cancer prevention and treatment. Tetrahedron Lett. 2008, 49 (50): 7178-7179. 10.1016/j.tetlet.2008.09.169.PubMedCentralCrossRefPubMed

10.

Hwang YP, Jeong HG: Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol. 2010, 242 (1): 18-28. 10.1016/j.taap.2009.09.009.CrossRefPubMed

11.

Morris CA, Avorn J: Internet marketing of herbal products. Jama. 2003, 290 (11): 1505-1509. 10.1001/jama.290.11.1505.CrossRefPubMed

12.

DeAngelis CD, Fontanarosa PB: Drugs alias dietary supplements. Jama. 2003, 290 (11): 1519-1520. 10.1001/jama.290.11.1519.CrossRefPubMed

13.

Dietz BM, Liu D, Hagos GK, Yao P, Schinkovitz A, Pro SM, Deng S, Farnsworth NR, Pauli GF, van Breemen RB, Bolton JL: Angelica sinensis and its alkylphthalides induce the detoxification enzyme NAD(P)H: quinone oxidoreductase 1 by alkylating Keap1. Chem Res Toxicol. 2008, 21 (10): 1939-1948. 10.1021/tx8001274.PubMedCentralCrossRefPubMed

14.

Yun TK: Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res. 2003, 523-524: 63-74.CrossRefPubMed

15.

Shibata S: Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci. 2001, 16 (Suppl): S28-37.PubMedCentralCrossRefPubMed

16.

Chang YS, Seo EK, Gyllenhaal C, Block KI: Panax ginseng: a role in cancer therapy?. Integr Cancer Ther. 2003, 2 (1): 13-33. 10.1177/1534735403251167.CrossRefPubMed

17.

Jia L, Zhao Y, Liang XJ: Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem. 2009, 16 (22): 2924-2942. 10.2174/092986709788803204.PubMedCentralCrossRefPubMed

18.

Xiang YZ, Shang HC, Gao XM, Zhang BL: A comparison of the ancient use of ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008, 22 (7): 851-858. 10.1002/ptr.2384.CrossRefPubMed

19.

Qi LW, Wang CZ, Yuan CS: American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol. 2010, 80 (7): 947-954. 10.1016/j.bcp.2010.06.023.CrossRefPubMed

20.

Ni W, Zhang X, Wang B, Chen Y, Han H, Fan Y, Zhou Y, Tai G: Antitumor activities and immunomodulatory effects of ginseng neutral polysaccharides in combination with 5-fluorouracil. J Med Food. 2010, 13 (2): 270-277. 10.1089/jmf.2009.1119.CrossRefPubMed

21.

Cheng H, Li S, Fan Y, Gao X, Hao M, Wang J, Zhang X, Tai G, Zhou Y: Comparative studies of the antiproliferative effects of ginseng polysaccharides on HT-29 human colon cancer cells. Med Oncol. 2010,

22.

Zeng Y: Adjunctive therapy of Ginseng Polysaccharide for lung cancer. China Pharmaceuticals. 2001, 10 (6): 31-32.

23.

Fu W, Chen L, Huang S, Zou H: The role of Panax ginseng polysaccharide injection in chemotherapy of patients with ovarian cancer. Pharm Care & Res. 2005, 5 (2): 169-171.

24.

Xie F, Zeng Z, Huang H, Zhao C, Lu T: Clinical observation on nasopharyngeal carcinoma treated with combined therapy of radiotherapy and ginseng polysaccharide injection. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001, 21 (5): 332-334.PubMed

25.

Liu J, Sun L, Zhao Y, Zhou T, Zhang J, Sui G, Wu J, Zhou J, Fu L, Lu Q, Liu G, Hui M: Clinical phase II study on immunoimprovement of patients with breast cancer treated by Shenyi capsule. Chin J Clin Oncol. 2000, 27 (7): 534-536.

26.

Liu S, Sun L, Ban L, Zhou T: Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Chin Clin Oncol. 2007, 12 (11): 847-849.

27.

Wang H, Li X: The application of shengmai injection in malignant tumor. Mod Chin Med. 2003, 16-17. 3

28.

Berenblum I, Armuth V: Two independent aspects of tumor promotion. Biochim Biophys Acta. 1981, 651 (1): 51-63.PubMed

29.

Heidelberger C, Freeman AE, Pienta RJ, Sivak A, Bertram JS, Casto BC, Dunkel VC, Francis MW, Kakunaga T, Little JB, Schechtman LM: Cell transformation by chemical agents--a review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res. 1983, 114 (3): 283-385.CrossRefPubMed

30.

Weinberg F, Chandel NS: Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009, 66 (23): 3663-3673. 10.1007/s00018-009-0099-y.CrossRefPubMed

31.

Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature. 2008, 454 (7203): 436-444. 10.1038/nature07205.CrossRefPubMed

32.

Aggarwal BB, Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006, 71 (10): 1397-1421. 10.1016/j.bcp.2006.02.009.CrossRefPubMed

33.

Juge N, Mithen RF, Traka M: Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007, 64 (9): 1105-1127. 10.1007/s00018-007-6484-5.CrossRefPubMed

34.

Wattenberg LW: Chemoprevention of cancer. Cancer Res. 1985, 45 (1): 1-8.PubMed

35.

Hsu CH, Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol. 2007, 595: 471-480. full_text.CrossRefPubMed

36.

Hatcher H, Planalp R, Cho J, Torti FM, Torti SV: Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008, 65 (11): 1631-1652. 10.1007/s00018-008-7452-4.CrossRefPubMed

37.

Xu C, Li CY, Kong AN: Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res. 2005, 28 (3): 249-268. 10.1007/BF02977789.CrossRefPubMed

38.

Valgimigli L, Iori R: Antioxidant and pro-oxidant capacities of ITCs. Environ Mol Mutagen. 2009, 50 (3): 222-237. 10.1002/em.20468.CrossRefPubMed

39.

Yu S, Kong AN: Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets. 2007, 7 (5): 416-424. 10.2174/156800907781386669.CrossRefPubMed

40.

Shen G, Kong AN: Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos. 2009, 30 (7): 345-355. 10.1002/bdd.680.PubMedCentralCrossRefPubMed

41.

Yuan JH, Li YQ, Yang XY: Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology. 2007, 80 (4): 269-278. 10.1159/000106447.CrossRefPubMed

42.

Yuan JH, Li YQ, Yang XY: Protective effects of epigallocatechin gallate on colon preneoplastic lesions induced by 2-amino-3-methylimidazo[4,5-f ] quinoline in mice. Mol Med. 2008, 14 (9-10): 590-598. 10.2119/2007-00050.Yuan.PubMedCentralCrossRefPubMed

43.

Kwak MK, Kensler TW: Targeting NRF2 signaling for cancer chemoprevention. Toxicol Appl Pharmacol. 2010, 244 (1): 66-76. 10.1016/j.taap.2009.08.028.PubMedCentralCrossRefPubMed

44.

Khor TO, Yu S, Kong AN: Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med. 2008, 74 (13): 1540-1547. 10.1055/s-0028-1088303.CrossRefPubMed

45.

Nair S, Li W, Kong AN: Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol Sin. 2007, 28 (4): 459-472. 10.1111/j.1745-7254.2007.00549.x.CrossRefPubMed

46.

Katoh Y, Iida K, Kang MI, Kobayashi A, Mizukami M, Tong KI, McMahon M, Hayes JD, Itoh K, Yamamoto M: Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys. 2005, 433 (2): 342-350. 10.1016/j.abb.2004.10.012.CrossRefPubMed

47.

Nguyen T, Nioi P, Pickett CB: The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem. 2009, 284 (20): 13291-13295. 10.1074/jbc.R900010200.PubMedCentralCrossRefPubMed

48.

Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S, Oo KT, Ma J, Kong AN: Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol Carcinog. 2006, 45 (11): 841-850. 10.1002/mc.20234.CrossRefPubMed

49.

Abraham NG, Kappas A: Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008, 60 (1): 79-127. 10.1124/pr.107.07104.CrossRefPubMed

50.

Moi P, Chan K, Asunis I, Cao A, Kan YW: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 1994, 91 (21): 9926-9930. 10.1073/pnas.91.21.9926.PubMedCentralCrossRefPubMed

51.

Kwak MK, Wakabayashi N, Kensler TW: Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat Res. 2004, 555 (1-2): 133-148.CrossRefPubMed

52.

Jeong WS, Jun M, Kong AN: Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid Redox Signal. 2006, 8 (1-2): 99-106. 10.1089/ars.2006.8.99.CrossRefPubMed

53.

Lee LS, Stephenson KK, Fahey JW, Parsons TL, Lietman PS, Andrade AS, Lei X, Yun H, Soon GH, Shen P, Danlshefsky S, Flexner C: Induction of chemoprotective phase 2 enzymes by ginseng and its components. Planta Med. 2009, 75 (10): 1129-1133. 10.1055/s-0029-1185508.CrossRefPubMed

54.

Halim M, Yee DJ, Sames D: Imaging induction of cytoprotective enzymes in intact human cells: coumberone, a metabolic reporter for human AKR1C enzymes reveals activation by panaxytriol, an active component of red ginseng. J Am Chem Soc. 2008, 130 (43): 14123-14128. 10.1021/ja801245y.CrossRefPubMed

55.

Park SH, Jang JH, Chen CY, Na HK, Surh YJ: A formulated red ginseng extract rescues PC12 cells from PCB-induced oxidative cell death through Nrf2-mediated upregulation of heme oxygenase-1 and glutamate cysteine ligase. Toxicology. 2010, 278 (1): 131-139.CrossRefPubMed

56.

Li J, Ichikawa T, Jin Y, Hofseth LJ, Nagarkatti P, Nagarkatti M, Windust A, Cui T: An essential role of Nrf2 in American ginseng-mediated anti-oxidative actions in cardiomyocytes. J Ethnopharmacol. 2010, 130 (2): 222-230. 10.1016/j.jep.2010.03.040.PubMedCentralCrossRefPubMed

57.

Kim SH, Park KS, Chang MJ, Sung JH: Effects of Panax ginseng extract on exercise-induced oxidative stress. J Sports Med Phys Fitness. 2005, 45 (2): 178-182.PubMed

58.

Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS: Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol. 2008, 48 (5): 599-609. 10.1177/0091270008314252.CrossRefPubMed

59.

Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, Xiao C, Zhang B, Gao Y: Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol. 2008, 601 (1-3): 73-78. 10.1016/j.ejphar.2008.10.057.CrossRefPubMed

60.

Kim J, Cha YN, Surh YJ: A protective role of nuclear erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res. 2010, 690 (1-2): 12-23.CrossRefPubMed

61.

Lin W, Wu RT, Wu T, Khor TO, Wang H, Kong AN: Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol. 2008, 76 (8): 967-973. 10.1016/j.bcp.2008.07.036.PubMedCentralCrossRefPubMed

62.

Liu H, Dinkova-Kostova AT, Talalay P: Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci USA. 2008, 105 (41): 15926-15931. 10.1073/pnas.0808346105.PubMedCentralCrossRefPubMed

63.

Dinkova-Kostova AT, Liby KT, Stephenson KK, Holtzclaw WD, Gao X, Suh N, Williams C, Risingsong R, Honda T, Gribble GW, Sporn MB, Talalay P: Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci USA. 2005, 102 (12): 4584-4589. 10.1073/pnas.0500815102.PubMedCentralCrossRefPubMed

64.

Ahn YH, Hwang Y, Liu H, Wang XJ, Zhang Y, Stephenson KK, Boronina TN, Cole RN, Dinkova-Kostova AT, Talalay P, Cole PA: Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci USA. 2010, 107 (21): 9590-9595. 10.1073/pnas.1004104107.PubMedCentralCrossRefPubMed

65.

Banning A, Florian S, Deubel S, Thalmann S, Muller-Schmehl K, Jacobasch G, Brigelius-Flohe R: GPx2 counteracts PGE2 production by dampening COX-2 and mPGES-1 expression in human colon cancer cells. Antioxid Redox Signal. 2008, 10 (9): 1491-1500. 10.1089/ars.2008.2047.CrossRefPubMed

66.

Park YC, Lee CH, Kang HS, Kim KW, Chung HT, Kim HD: Ginsenoside-Rh1 and Rh2 inhibit the induction of nitric oxide synthesis in murine peritoneal macrophages. Biochem Mol Biol Int. 1996, 40 (4): 751-757.PubMed

67.

Surh YJ, Na HK, Lee JY, Keum YS: Molecular mechanisms underlying anti-tumor promoting activities of heat-processed Panax ginseng C.A. Meyer. J Korean Med Sci. 2001, 16 (Suppl): S38-41.PubMedCentralCrossRefPubMed

68.

Kim ND, Pokharel YR, Kang KW: Ginsenoside Rd enhances glutathione levels in H4IIE cells via NF-kappaB-dependent gamma-glutamylcysteine ligase induction. Pharmazie. 2007, 62 (12): 933-936.PubMed

69.

Oh GS, Pae HO, Choi BM, Seo EA, Kim DH, Shin MK, Kim JD, Kim JB, Chung HT: 20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-kappaB in RAW 264.7 macrophages stimulated with lipopolysaccharide. Cancer Lett. 2004, 205 (1): 23-29. 10.1016/j.canlet.2003.09.037.CrossRefPubMed

70.

Darnell JE: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002, 2 (10): 740-749. 10.1038/nrc906.CrossRefPubMed

71.

Richmond A: Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol. 2002, 2 (9): 664-674. 10.1038/nri887.PubMedCentralCrossRefPubMed

72.

Nair S, Doh ST, Chan JY, Kong AN, Cai L: Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. Br J Cancer. 2008, 99 (12): 2070-2082. 10.1038/sj.bjc.6604703.PubMedCentralCrossRefPubMed

73.

Wang H, Khor TO, Saw CL, Lin W, Wu T, Huang Y, Kong AN: Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol Pharm. 2010,

74.

Kuang X, Scofield VL, Yan M, Stoica G, Liu N, Wong PK: Attenuation of oxidative stress, inflammation and apoptosis by minocycline prevents retrovirus-induced neurodegeneration in mice. Brain Res. 2009, 1286: 174-184. 10.1016/j.brainres.2009.06.007.PubMedCentralCrossRefPubMed

75.

Cho HY, Gladwell W, Wang X, Chorley B, Bell D, Reddy SP, Kleeberger SR: Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice. Am J Respir Crit Care Med. 2010, 182 (2): 170-182. 10.1164/rccm.200907-1047OC.PubMedCentralCrossRefPubMed

76.

Saw CL, Huang Y, Kong AN: Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. 2010, 79 (3): 421-430. 10.1016/j.bcp.2009.08.030.CrossRefPubMed

77.

Cheung KL, Khor TO, Kong AN: Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res. 2009, 26 (1): 224-231. 10.1007/s11095-008-9734-9.CrossRefPubMed

Title: Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways
Authors: Constance Lay-Lay Saw
Qing Wu
Ah-NgTony Kong
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Chinese Medicine / Issue 1/2010
Electronic ISSN: 1749-8546
DOI: https://doi.org/10.1186/1749-8546-5-37

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Semantic Web for data harmonization in Chinese medicine

Quality assurance for Chinese herbal formulae: standardization of IBS-20, a 20-herb preparation

Preventive effects of Flos Perariae (Gehua) water extract and its active ingredient puerarin in rodent alcoholism models

Reduction of chronic non-specific low back pain: A randomised controlled clinical trial on acupuncture and baclofen

Polysaccharopeptides derived from Coriolus versicolor potentiate the S-phase specific cytotoxicity of Camptothecin (CPT) on human leukemia HL-60 cells

Osteoprotective effects of Fructus Ligustri Lucidi aqueous extract in aged ovariectomized rats